Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
Berger, Jeffrey S; Katona, Brian G; Jones, W Schuyler; Patel, Manesh R; Norgren, Lars; Baumgartner, Iris; Blomster, Juuso; Mahaffey, Kenneth W; Held, Peter; Millegård, Marcus; Heizer, Gretchen; Reist, Craig; Fowkes, F Gerry; Hiatt, William R.
Am Heart J
; 175: 86-93, 2016 May.
Artigo em Inglês | MEDLINE | ID: mdl-27179727
Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease.
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
Adverse cardiovascular outcomes in relation to suboptimal antithrombotic therapy use in patients undergoing peripheral artery disease angioplasty: lost opportunities?
Perioperative clopidogrel is associated with increased bleeding and blood transfusion at the time of lower extremity bypass.
Review of aspirin and clopidogrel resistance in peripheral arterial disease.
[Comparative assessment of antiaggregant efficacy of acetylsalicylic acid and clopidogrel in peripheral atherosclerosis].
Complications of transbrachial arterial access for peripheral endovascular interventions.
High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values.
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.